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Abstract IRS proteins are cellular adaptor molecules that
mediate many of the key metabolic actions of insulin.
When tyrosine is phosphorylated by the activated insulin
receptor, IRS proteins recruit downstream effectors, such
as phosphoinositide 3-kinase and mitogen-activated protein
kinase, in order to elicit cellular responses such as glucose
uptake, lipid metabolism and cell proliferation. There are
two main IRS proteins in humans (IRS1 and IRS2), both
of which are widely expressed. Given their central role in
the insulin signalling pathway, it is not surprising that male
mice lacking Irs1 or Irs2 present with elevated blood glu-
cose or type 2 diabetes, respectively. For reasons yet to be
identified, female Irs2−/− mice do not develop type 2 dia-
betes. A number of organs are affected by complications of
diabetes; macrovascular complications include stroke and
coronary artery disease, while nephropathy, neuropathy
and retinopathy fall into the category of microvascular
complications. Given the serious consequences of these
complications on patient morbidity and mortality, it is es-
sential to identify the molecular pathogenesis underlying
diabetic complications, with a view to improving therapeu-
tic intervention and patient outcomes. A number of recently
published papers have converged on the hypothesis that the
loss of insulin signalling and IRS proteins is instrumental
to the development and/or progression of diabetic
complications. This review will summarise some highlights
from the published work in which this hypothesis is
discussed.
Keywords Diabetic complications . Eye . Heart . Insulin .
Insulin receptor substrate . Kidney . Neuron . Review
Abbreviations
ApoE Apolipoprotein E
CAD Coronary artery disease
CVD Cardiovascular disease
ESRD End-stage renal disease
eNOS Endothelial nitric oxide synthase
ET-1 Endothelin-1
GBM Glomerular basement membrane
GLP-1 Glucagon-like peptide-1
GSK3β Glycogen synthase kinase 3 β
HIF-2α Hypoxia-inducible factor-2α
HO-1 Haemoxygenase-1
IGF-1R IGF-1 receptor
IGFBP-2 IGF binding protein 2
IR Insulin receptor
Ikkβ Inhibitor of nuclear factor κ-B kinase subunit β
JAK2 Janus kinase 2
JNK c-Jun N-terminal kinase
MI Myocardial infarction
mTORC Mammalian target of rapamycin complex
MAPK Mitogen-activated protein kinase
PAI-1 Plasminogen activator inhibitor-1
PH Pleckstrin homology
PI3K Phosphoinositide 3-kinase
PKB Protein kinase B/Akt
PKCβ Protein kinase Cβ
PodIRKO Podocyte-specific Insr-knockout
* Derek P. Brazil
d.brazil@qub.ac.uk
1 Centre for Experimental Medicine, School of Medicine, Dentistry
and Biomedical Sciences, Queen’s University Belfast, 97 Lisburn
Road, Belfast BT9 7BL, Northern Ireland, UK
2 Division of Endocrinology, Children’s Hospital Boston, Harvard
Medical School, Boston, MA, USA
Diabetologia (2016) 59:2280–2291
DOI 10.1007/s00125-016-4072-7
PPARγ Peroxisome proliferator-activated receptor-γ
PTB Phosphotyrosine binding
SNP Single-nucleotide polymorphism
STAT3 Signal transducer and activator of
transcription 3
STZ Streptozotocin
VCAM-1 Vascular cell adhesion molecule-1
VEGF Vascular endothelial growth factor
Highlights
• IRS proteins and cardiovascular disease
• IRS proteins and diabetic nephropathy
• IRS proteins in diabetic retinopathy
• IRS proteins in the brain
• IRS proteins in diabetic neuropathy
Introduction
Insulin and IGF signalling require a family of scaffold proteins
(IRS proteins) to integrate extracellular signals into intracellu-
lar responses, leading to cellular effects. There are two main
IRS proteins in humans, IRS1 and IRS2, which are widely
expressed in most human (and mammalian) tissues, whilst a
third protein, IRS4, is mainly expressed in the hypothalamus
[1]. All IRS proteins consist of an amino terminal pleckstrin
homology (PH) domain and a phosphotyrosine binding (PTB)
domain, followed by a long tail of tyrosine residues that act as
phosphorylation sites to drive insulin/IGF-1 signalling [2].
IRS proteins can also be phosphorylated on Ser and Thr res-
idues, and the majority of evidence suggests that this leads to
reduced IRS protein expression and attenuated insulin signal-
ling. Although similar in structure and sequence, the IRS pro-
teins possess distinct roles in mammalian physiology. This is
beautifully illustrated by the phenotypes of Irs1- vs Irs2-
knockout mice. Male mice lacking Irs1 have a small body
size, and increased beta cell mass accompanied by mild met-
abolic defects [3, 4]. In contrast, male Irs2−/−mice are normal
in size but develop diabetes at around 8 weeks, due to hepatic
and peripheral insulin resistance and pancreatic beta cell in-
sufficiency [3, 5]. The primary signalling pathway activated
by IRS proteins is the phosphoinositide 3-kinase (PI3K)–pro-
tein kinase B (PKB/Akt) cascade, which regulates many
downstream effectors such as glycogen synthase kinase 3β
(GSK3β), mammalian target of rapamycin complex 1
(mTORC1) and mTORC2, and Forkhead transcription factors
[2]. Changes in IRS protein function have been well studied in
diabetes, in mouse models and human samples. This review
will summarise a wealth of data describing the role of IRS
proteins in diabetic complications, many of which may in-
volve altered insulin and IGF-1 signalling as causal factors.
IRS proteins and cardiovascular disease
Diabetes significantly increases the risks of cardiovascular dis-
ease (CVD). In the UK, CVD accounts for 48% of fatalities in
people with either type 1 or type 2 diabetes [6, 7]. The risk of
stroke, angina, myocardial infarction (MI) and heart failure is
approximately double in diabetic patients. Intensive control of
blood glucose has been shown to decrease the risk of non-fatal
heart attack, stroke or death from CVD by 57% in diabetic
patients [8]. Insulin has been proposed to mediate an anti-
atherogenic effect on blood vessels via IRS–PI3K–Akt signal-
ling [9]. This leads to activation of endothelial nitric oxide
synthase (eNOS), expression of haemoxygenase-1 (HO-1)
and vascular endothelial growth factor (VEGF) and decreased
expression of vascular cell adhesionmolecule-1 (VCAM-1), all
of which are protective against vascular damage [9]. In contrast,
insulin-mediated activation of growth factor receptor bound
protein-2 / SH2-containing proto-oncogene / mitogen-
activated protein kinase (MAPK) mediates a pro-atherogenic
effect, increasing expression of endothelin-1 (ET-1) and plas-
minogen activator inhibitor-1 (PAI-1) and increasing the prolif-
eration of contractile cells in the blood vessels [9]. In diabetes,
which is characterised by an absence of insulin or increased
peripheral insulin resistance (or both), a reduction in insulin
receptor (IR) to IRS to PI3K to Akt signalling leads to acceler-
ation of atherosclerosis because of the loss of anti-atherogenic
insulin signalling [9]. Angiotensin II, NEFA and TNF-α con-
tribute to this effect by increasing serine phosphorylation of
IRS proteins, which leads to decreased Akt activation, reduced
VEGF expression and poorer outcomes in CVD [9]. Protein
kinase Cβ (PKCβ) isoforms such as PKCβ2 have been impli-
cated in IRS2 phosphorylation on Ser303 and Ser675, leading
to negative regulation of IRS2 tyrosine phosphorylation and
reduced insulin signalling [10]. In addition, PKC inhibitors
such as ruboxistaurin have been shown to reduce the severity
of myocardial injury in rodent models of diabetic heart disease
[11–13] and in a pig model of MI [14].
The essential role of insulin in healthy heart and blood
vessel function has been highlighted by studies in which the
IR was deleted from cardiac muscle and endothelial cells.
Mice lacking IR expression in cardiac muscle (MIRKO)
showed impaired cardiac performance at 6 months [15].
When these MIRKO mice had a single copy of Igfr1 deleted,
they died within 4 weeks of birth due to dilated cardiomyop-
athy [15]. Similarly, endothelial cell-specific Insr-knockout
mice (EIRKO) displayed accelerated atherosclerosis when
crossed with apolipoprotein E (ApoE) null mice [16].
Analysis of left ventricular myocardial biopsies from humans
with type 1 diabetes showed a surprising increase in IR to
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IRS1 to PI3K to Akt signalling [17]. These changes were
accompanied by a decrease in GLUT4 expression in the sar-
colemma, suggesting defective myocardial insulin resistance
in type 1 diabetes. This hypothesis is supported by data from
the ob/ob model of type 2 diabetes, which, along with other
data from animal models, is shown in Table 1.
Data from human studies Several epidemiological studies
have identified polymorphisms that implicate IRS proteins in
the incidence of diabetic complications. A specific Gly(972)Arg
substitution mutation in the IRS1 gene is a significant indepen-
dent predictor of coronary artery disease (CAD) [18]. IRS1
Gly(972)Arg mutations were detected in 6.8% of control and
18.9% of individuals with coronary atherosclerosis identified by
angiography [18]. The IRS1 Gly(972)Arg mutation was associ-
ated with an increased risk of CAD, independent of other factors
such as smoking or hypertension, with an additional increase in
risk in obese individuals or those with insulin resistance syn-
drome [18]. Diabetes incidence and plasma triacylglycerol levels
are increased in CAD Gly(972)Arg mutation carriers compared
with non-carriers [18]. Interestingly, IRS1Gly(972)Argmutations
were observed in 5.8% of the general population and 10.7% of
individuals with type 2 diabetes, suggesting a genetic basis for
increased CAD in the diabetic population [19].
A meta-analysis of 27 studies, carried out by Jellema et al,
showed that IRS1 Gly(972)Arg carriers had a 25% greater risk
of developing type 2 diabetes [20]. Liu et al showed that the
IRS1 Gly(972)Arg mutation associates with serum ACE2
levels in patients following acute MI [21]. ACE2 was signifi-
cantly elevated in acute MI patients vs control; however IRS1
Gly(972)Arg carriers with acuteMI had significantly decreased
levels of ACE2, presenting with a more severe MI and a poorer
prognosis [21]. As ACE2 negatively regulates the renin–angio-
tensin system, it has a cardioprotective role following its acti-
vation post MI and counteracts the adverse cardiac renin-
angiotensin system effects [21]. In the presence of insulin,
and under hypoxic conditions in vitro, IRS1 Gly(972)Arg
inhibited ACE2 expression in human cardiomyocytes, reveal-
ing a possible link between insulin and IRS protein signalling
and cardiac renin–angiotensin system activation [21]. Another
case–control study has supporting data from subjects of Punjabi
origin, where IRS1 Gly(972)Arg carriers or Arg homozygous
individuals had a higher risk of CAD in the overall population
[22]. However, contradictory data from a case–control study by
Strohmer et al showed no association between the Gly(972)Arg
mutation and CAD in male or female patients, or in obese
patients, in the Austrian population, although the power of this
study required to determine a causal role was suboptimal [23].
Data from Vats et al have shown that a single-nucleotide poly-
morphism (SNP) in IRS2—Gly(1057)Asp—is also associated
with CAD, where Gly(1057)Asp carriers or Asp1057 homozy-
gous individuals have an increased risk of developing CAD in
the overall population of Punjabi origin, and in obese individ-
uals [22]. Chan et al have shown that in the Taiwanese popu-
lation, IRS2 Gly1057 homozygous/heterozygous individuals
are at increased risk of developing CAD, whereas Asp/
Table 1 Summary of data linking IRS proteins to cardiac dysfunction
IRS
involved
Mouse model Organ
affected
Main findings Reference
IRS1, IRS2 Myocardium-specific
Irs1−/−; Irs2−/− mice
Heart In the absence of both Irs1 and Irs2, thinning walls, global dilatation,
diastolic failure and decreased systolic activity were evident. Heart
failure markers such as β-myosin heavy chain increased and
interstitial fibrosis was associated with increased TGFβ1 and
collagen 1 mRNA. Myocardium-specific Irs1−/−; Irs2−/− mice died at
6–8 weeks of age, yet heterozygous myocardium Irs1+/−; Irs2+/−
mice survived to at least 6 months of age before fatal cardiac
dysfunction developed
Qi et al (2013) [78]
Mice with specific hepatic
deletion of Irs1 and Irs2
Liver Hepatic deletion of Irs1 and Irs2 caused a decrease in cardiac IRS1 and
IRS2, and similar, albeit less severe, effects on the heart were observed.
These mice showed p38MAPK activation, which mediated IRS protein
degradation in response to chronic insulin stimulation. These data
suggest a new link between hepatic insulin signalling and IRS protein
levels in the heart
Qi et al (2013) [78]
IRS1 ob/ob mice (model of
type 2 diabetes)
Heart Myocardial IRS1–PI3K activity was significantly increased in ob/ob mice
vs control. These data were similar to IRS1–PI3K activity in both
individuals with type 2 diabetes and those with left ventricular dysfunction,
whose myocardium was insulin resistant. IR-β, IRS1 and total and
phospho-Akt were also increased in ob/ob mice; however, total IRS1
was unchanged in individuals with type 2 diabetes and left ventricular
dysfunction. Insulin-induced Akt phosphorylation was greater in control
mice than in ob/ob mice with no alterations in total Akt
Cook et al
(2010) [17]a
aMouse- and human-based research summarised
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Asp1057 individuals are protected against CAD [24].
However, further confirmation is needed due to some limita-
tions of the study [24].
Diminished insulin to IRS signalling has been implicated in
the poor prognosis of diabetic patients following a stroke [25].
Similar to the heart, insulin mediates a protective effect on
cerebral blood vessels, and insulin resistance is implicated in
increased stroke incidence in diabetes. Tight control of glu-
cose reduces the risk of non-fatal stroke by 57% [8, 26], via
similar protective mechanisms to those discussed above. IRS
proteins may play a role in the response of neurons to ischae-
mia, as in a mouse model of obesity-induced type 2 diabetes
there was reduced IRS to PI3K to Akt signalling in the brain
[27]. In a recent study of type 2 diabetes patients, Zhang et al
found that polymorphisms in IRS1 were associated with
higher platelet activity and suboptimal responses to drugs
such as clopidogrel (Plavix), which is used to prevent platelet
adhesion in patients at risk of stroke [28]. A summary of IRS
signalling in the brain is provided later in this review.
IRS proteins and diabetic nephropathy
Diabetic nephropathy is the leading cause of end-stage renal
disease (ESRD)worldwide. Up to 40% of individuals with type
1 or type 2 diabetes will have clinically evident kidney disease
during their lifetime [29]. The annual cost of chronic kidney
disease to the National Health Service in England is estimated
to be £1.45 billion [30]. Current treatment of diabetic nephrop-
athy relies on tight glycaemic control, together with improved
control of systemic and intraglomerular hypertension, using
ACE inhibitors or angiotensin II receptor blockers as the main-
stays of therapy [29]. Insulin signalling plays a critical role in
kidney cell physiology and in the maintenance of the glomer-
ular basement membrane (GBM). Defects in insulin signalling
have been implicated in diabetic nephropathy at the level of the
IR and IRS proteins (Table 2). The glomerular podocyte, the
interdigitated foot processes of which form part of the GBM,
responds to insulin by increasing glucose uptake via GLUT1
and GLUT4 transporters [31]. Nephrin is needed for this re-
sponse, as it facilitates translocation of GLUT proteins to the
plasma membrane via synaptobrevin (VAMP-2) binding [32].
The significance of these data for glomerular function in vivo
was highlighted by the generation of podocyte-specific Insr-
knockout (PodIRKO) mice [33]. At 8 weeks of age, PodIRKO
mice developed podocyte foot effacement, apoptosis and albu-
minuria, accompanied by increased type IV collagen staining
and glomerulosclerosis [33]. The likely mechanism for this
diabetic nephropathy-like phenotype in PodIRKO mice was
reduced VEGF-A production, which is stimulated by insulin
in podocytes in vitro and in vivo [34]. These data tally with
previous reports detailing defective filtration barrier develop-
ment and diabetic nephropathy-like symptoms in mice lacking
VEGF-A in podocytes [35]. Given the critical role of insulin
signalling pathways in podocyte and GBM function, it is per-
haps not surprising that numerous reports have also identified
roles for IRS proteins in a range of kidney cells from mouse
models. For example, IRS2 expression is enriched in glomer-
ular podocytes, and podocytes from Irs2−/− mice are signifi-
cantly insulin resistant, suggesting a dominance of IRS2 over
IRS1 in these cells [36]. IRS2 is also overexpressed in kidney
tubular epithelial cells in biopsies from humans with diabetic
nephropathy [37]. More data supporting a role for IRS protein
in diabetic kidney are summarised in Table 2.
Epidemiology data on IRS proteins in diabetic nephropa-
thy Decreasing GFR is widely accepted as a hallmark of dia-
betic nephropathy, where an inverse relationship exists between
GFR and the progressive stages of diabetic nephropathy [38].
A region on chromosome 2q35-37 was highlighted in a cohort
of Mexican-American diabetes patients as an area with the
strongest GFR linkage [39]. Within this region, IRS1was iden-
tified as a potential candidate gene [39]. Of note, this IRS1
mutation is also associated with increased risk of CAD (see
above). IRS1 SNPs were identified and analysed in Mexican-
American individuals, to identify links between declining GFR
and type 2 diabetes [39]. A specific missense mutation in IRS1
occurring at codon 972 (Gly[972]Arg) was found to be the only
SNP out of 18 that conferred association with GFR and serum
triacylglycerol levels [39]. This SNP was responsible for 26%
of the GFR–chromosome 2q linkage, with carriers of this mu-
tation presenting with significantly lower GFR [39].
Consistently, human mesangial cells transfected with mutant
Gly(972)Arg IRS1 displayed lower insulin-induced phosphor-
ylation of IRS1 and Akt [39]. These data suggest that even a
single mutated codon in IRS1 can negatively influence insulin
signalling and an individual’s GFR and renal function.
Chromosome 13q33.3 has also been implicated as a dia-
betic nephropathy susceptibility locus in patients with type 1
or type 2 diabetes [40]. This particular locus is situated at an
intergenic region close to both MYO16 (encoding myosin
heavy chain Myr 8) and IRS2 [40], which is located in region
13q34 [41]. Following a genome-wide association scan of the
Genetics of Kidneys in Diabetes (GoKinD) collections,
13q33.3 was one of four loci associated with diabetic ne-
phropathy in patients with type 1 diabetes [40]. In a
Japanese subset of patients with type 2 diabetes, SNPs in these
same loci increased diabetic nephropathy risk [40]. In the
Joslin Study of Genetics of Nephrology in Type 2 Diabetes
collection, multiple SNPs on chromosome 13q33.3 were iden-
tified with one particular SNP (rs1411766) exclusively asso-
ciated with risk of early diabetic nephropathy and a trend
towards an association with diabetic nephropathy in type 2
diabetes [40]. These data suggest that inherited changes in or
around the IRS2 gene may contribute to the genetic
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predisposition or increased risk of developing diabetic ne-
phropathy in some diabetic patients.
IRS proteins in diabetic nephropathy: a novel therapeutic
target? Given the changes in IRS proteins in the diabetic
kidney, the question arises: can we alter IRS protein levels to
provide benefit and reduce the severity of diabetic nephropathy
in patients? A second question arises: would increasing or de-
creasing IRS protein levels (and therefore insulin signalling) be
of benefit in the diabetic kidney? Data from the Coward group
Table 2 Summary of data describing roles for IRS proteins in kidney function and diabetic nephropathy
IRS protein
involved
Rodent genotype/phenotype Kidney region/cell
affected
Main findings Reference
IRS1 OLETF rats that developed
diabetes and overt
nephropathy
Renal cortex IRS1 protein expression significantly reduced
vs control LETO rats
Nakamura et al
(2015) [79]
IRS1 ROP mice Isolated mesangial
cells
High glucose increased total IRS1 protein
expression and IRS1 phosphorylation in
mesangial cells from glomerulosclerosis-prone
ROP mice, and levels of IGF-1 receptor and
IGF-1 also increased. This is consistent with
previous data implicating IRS1 as the main IRS
protein involved in IGF-1 signalling. ROP
mesangial cells expressed less IGFBP-2 vs
control mice, and individuals with DN presented
with reduced IGFBP-2 in glomeruli vs control
individuals, indicating the potential for
IGFBP-2 as a marker identifying patient
susceptibility to DN. Low levels of IGFBP-2
may play a partial role in increased IGF-1
signalling via IRS1, as treatment of ROP
mesangial cells with exogenous IGFBP-2
reduced glucose-induced increases in IRS1
phosphorylation, protecting cells from
further damage
Fornoni et al
(2006) [80]a;
Myers et al
(1993) [81]
IRS1 NOD mice Isolated mesangial
cells
Mesangial cells from NOD mice (model of type 1
diabetes) with nephropathy displayed phenotypic
changes such as IGF-1 signalling pathway
activation
Fornoni et al
(2006) [80]
IRS1 db/db mice Isolated mesangial
cells
Mesangial cells from db/db mice (model of type 2
diabetes) also displayed phenotypic changes, such
as IGF-1 signalling pathway activation
Fornoni et al
(2006) [80]
IRS1 C57BL/6 mice Isolated mesangial
cells
High glucose treatment of control mesangial cells from
glomerulosclerosis-resistant C57BL/6 mice yielded
changes that were similar to those observed with
mesangial cells from NOD and db/db mice. These
data suggest that both type 1 and type 2 diabetes
stimulate the IGF-1 pathway
Fornoni et al
(2006) [80]
IRS2 Wild-type, Irs1−/−
and Irs2−/− mice
Proximal tubule
epithelial cells
Insulin-induced increases in tubular bicarbonate ion
absorption and Akt phosphorylation were seen in
wild-type mice, and this effect was decreased in
Irs2−/− mice. No defects in bicarbonate absorption
were seen in Irs1−/− mice, suggesting that IRS2
coordinates the effects of insulin upon tubular
epithelial cell bicarbonate transport
Zheng et al
(2005) [82]
IRS2 Wild-type mice Tubular epithelial
cells
IRS2 expression detected in embryonic kidney
tubules, adult proximal and distal tubules and
cortical collecting duct. BMP-7 increased IRS2
signalling in HK-2 proximal tubule epithelial cells
Hookham et
al (2013) [37]
IRS2 Irs2−/− mice Podocytes Irs2−/− podocytes were found to be insulin resistant
with respect to Akt signalling and GLUT4-mediated
glucose uptake in response to insulin
Santamaria et
al (2015) [36]
aMouse- and human-based research summarised
DN, Diabetic nephropathy; IGFBP-2, IGF binding protein-2; LETO, Long–Evans Tokushima Otsuka (rats); OLETF, Otsuka Long–Evans Tokushima
fatty (rats); ROP, ragged olygosyndactilism pintail (mice)
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showed that insulin-mediated VEGF production is critical for
podocyte survival in the kidney, suggesting that increasing IRS
protein levels may help to rescue insulin signalling in the dia-
betic kidney [33]. However, treatment of db/db mice with bio-
active peptides nephrilin or anephril significantly reduced
IRS2, p-IRS1-Ser307, serum/glucocorticoid-regulated kinase
1 and phospho-PKC-α/β which, when elevated, are associated
with diabetic nephropathy [42]. A concomitant decrease in al-
buminuria was also detected in these mice, suggesting a bene-
ficial effect of these peptides on renal function [41].
Streptozotocin (STZ)-treated mice yielded higher nuclear ex-
pression of IRS2, Rictor and phospho-PKC in fractionated re-
nal tissue extracts, which was reduced by nephrilin in vivo [42].
These data suggest that, as a component of mTORC2, a nuclear
complex of IRS2 and Rictor exists that is disrupted by
nephrilin, potentially implicating this complex in albuminuria
in diabetic nephropathy [42]. In contrast, data from Wei et al
suggest that modulation of hypoxia-mediated regulation of
IRS2 in the liver can sensitise hepatic insulin signalling [43].
VEGF inhibition improved glucose tolerance in db/db mice
and this augmented insulin signalling via IRS2 induction.
Hepatic hypoxia was induced, which subsequently activated
hepatic hypoxia-inducible factor-2α (HIF-2α) and improved
insulin signalling as HIF-2α promotes IRS2 expression [43].
Complementary work from Taniguchi et al showed that specif-
ic hepatic deletion of the gene encoding prolyl hydroxylase 3
(Phd3, also known as Egln1) in mice modified insulin sensitiv-
ity by eliciting HIF-2α stabilisation, resulting in greater IRS2
transcription and downstreamAkt signalling [44]. The relation-
ship between HIF-2α and IRS2 therefore provides a new ther-
apeutic approach to increase IRS2 levels in the treatment of
diabetes and related complications, should this be demonstrated
to be therapeutically advantageous in patients [44]. We and
others are currently exploring the effects of increasing IRS2
levels in the diabetic kidney using similar hypoxia-mediated
strategies.
IRS proteins in diabetic retinopathy
Diabetic retinopathy is a commonmicrovascular complication
of diabetes characterised by damage to a number of retinal cell
types including retinal pigment epithelia, Müller cells and
retinal vascular cells [45]. A significant feature of diabetic
retinopathy is the loss of retinal blood vessels, leading to ret-
inal ischaemia/hypoxia and then to pathogenic neovasculari-
sation and progressive vision loss [46]. IRS proteins are
expressed in the normal retina, and both IRS1 and IRS2 have
been implicated in normal retinal development and diabetic
retinopathy. Some of these data are discussed below.
Retinal Müller cells: a primary site of IRS signalling in the
retina IRS proteins are heavily phosphorylated on tyrosine,
serine and threonine residues [37, 47, 48]. Aguirre et al origi-
nally showed that c-Jun N-terminal kinase (JNK)-induced
IRS1Ser307 phosphorylation prevents IR–IRS interactions,
resulting in impaired insulin signalling [49, 50]. In contrast,
Copps et al showed that substitution of Ser307 with Ala result-
ed in severe insulin resistance and impaired insulin signalling,
thus positively implicating Ser307 in maintaining insulin sig-
nalling and sensitivity [27]. With regard to the retina, the
Steinle group showed in both rat retinalMüller cells and human
retinal endothelial cells grown in high glucose, that TNF-α
increased IRS1Ser307 phosphorylation, insulin resistance and
retinal cell death [51–53]. This effect was reversed by the β-
adrenergic agonist salmeterol, suggesting that β-adrenergic re-
ceptor agonists can restore insulin signalling and protect retinal
Müller cells from apoptosis in diabetes [53]. Similar effects
were seen in retinal endothelial cells, where hyperglycaemia
caused elevated TNF-α, increased IRS1Ser307 phosphorylation
and loss of IRS1 protein, likely via suppressor of cytokine
signalling 3 (SOCS3)-mediated targeting to the proteasome
[54]. Given the critical role of retinal capillary loss during dia-
betic retinopathy pathogenesis, these data provide evidence that
rescuing insulin signalling may decrease retinal endothelial cell
apoptosis, thus potentially improving diabetic retinopathy out-
comes. Supporting this hypothesis, two reports indicated that
pioglitazone, a peroxisome proliferator-activated receptor-γ
(PPARγ) agonist reduced TNF-α-mediated IRS1Ser307 phos-
phorylation and insulin resistance in diabetic rat retinas, with
a concomitant improvement in retinal function [55].
Pioglitazone was shown to decrease Müller cell and retinal
endothelial cell apoptosis, likely via increased insulin-
mediated pro-survival signalling [55]. Similar data were obtain-
ed using sodium salicylate [56], which was shown to reverse
insulin resistance via inhibition of TNF-α-mediated Ikkβ-
driven inflammatory responses [57, 58].
Mouse models have also demonstrated key roles for IRS
proteins in retinal development as well as disease. A summary
of these data is shown in Table 3.
IRS proteins in the brain
The main diabetic complication affecting the brain is the in-
creased risk of stroke (discussed above). However, defective
insulin signalling has also been identified in the central ner-
vous system in diabetes, and has been linked to altered nutri-
ent homeostasis, an increased risk of Alzheimer’s disease and
changes in lifespan. The role of insulin signalling in the brain
has been reviewed expertly elsewhere [59]. The main effects
of insulin in the brain appear to be on energy homeostasis,
neuronal proliferation, Tau phosphorylation and reproductive
endocrinology [59]. Centrally administered insulin can im-
prove peripheral insulin sensitivity in the liver by reducing
hepatic glucose production [60]. Mice lacking the IR in
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neurons (NIRKOmice) developed diet-sensitive obesity, with
increased body fat and plasma leptin levels [61]. Female mice
lacking IRS2 are infertile, due to reduced levels of luteinising
hormone, prolactin and sex steroids, linking insulin signalling
to hypothalamic control of reproductive endocrinology [62].
IRS2 expression in the hypothalamus is also important in en-
ergy homeostasis, as mice lacking IRS2 in a specific subset of
hypothalamic neurons display hyperphagia, obesity and in-
creased body length [63]. Whole-body Irs2−/− mice have
brains that are 30% smaller than wild-types, due to a defect
in neuronal proliferation during development [64]. Elevated
Tau phosphorylation was also detected in Irs2−/− mouse
brains, suggesting a potential link between IRS2 and
Alzheimer’s disease [64]. Consistently, levels of IRS2 (and
IRS1) were reduced in the neurons of the temporal cortex of
post-mortem human brains from Alzheimer’s patients
compared with controls [65]. Others have demonstrated
post-mortem insulin resistance in the brains of Alzheimer’s
patients, specifically in the hippocampus, providing a link to
cognitive defects and decreased memory formation [66]. Mice
lacking IRS2 demonstrated deficiencies in N-methyl-D-aspar-
tate receptor-mediated long-term potentiation and hippocam-
pal plasticity [67, 68]. Increased serine phosphorylation of
IRS proteins, a feature of insulin resistance, was also detected
in the brains of Alzheimer’s patients [66]. Co-localisation of
pSer-IRS1 and amyloid-β was demonstrated in these brains,
and amyloid-β oligomers injected directly into the brain stim-
ulated IRS1 protein phosphorylation and JNK activation [69].
Importantly, exendin-4, a glucose-lowering drug that activates
glucagon-like peptide-1 (GLP-1) signalling, was shown to
prevent this amyloid-β-induced insulin resistance and in-
crease spatial memory in non-diabetic mice [69]. Together,
Table 3 Summary of data linking IRS proteins to diabetic retinopathy
IRS
involved
Rodent genotype/
phenotype
Organ
affected
Main findings Reference
IRS2 Irs2−/− mice Eye (retina) Irs2 gene deletion triggered photoreceptor apoptosis with a 50%
reduction in cells by day 14, with almost complete photoreceptor
loss by 16 months of age. In contrast, normal retinal
morphology was maintained in Irs1−/− mice at up to 2 years of
age. Retinas from Irs2−/− mice displayed higher caspase-3
cleavage and activation, and lower Akt phosphorylation,
consistent with apoptotic cell death. Expression of rhodopsin
(the light-sensing G-protein-coupled receptor in the retina) was
reduced in Irs2−/− retinas and retinal electrical function showed
that Irs2−/− mice had reduced dark- and light-adapted responses,
suggesting lower rod and cone activity, respectively
Yi et al (2005) [45]
IRS2 9- and 12-week-old
Irs2−/− mice
Eye (retina) At 9 weeks, activation of Müller glial cells was apparent, as
demonstrated by outer retinal layers that were considerably
thinner than their wild-type counterparts. Thinning extended to
each retinal layer in 12-week-old Irs2−/− mice. Changes in
microglia were also detected at 9 weeks with
swelling/retraction of microglial processes observed. In both
age groups, shortened rod segments were apparent, and
rhodopsin distribution in the rod photoreceptors of the outer
nuclear layer was abnormal. Photoreceptor atrophy, as well as
synaptic changes at the outer plexiform layer were also
observed. Retinal ganglion cell degeneration was present in
12-week-old Irs2−/− mice with the progressive loss of these
cells observed
Albert-Fort et al (2014)
[83]; Kern and
Barber (2008) [84]
IRS1, IRS2 STZ-induced
model of type 1 diabetes
in Sprague–Dawley
rats
Eye (retina) At 1 month post STZ-induced diabetes, retinal IRS1/2-associated
PI3K activity, Akt1 and Akt3 kinase activity, and
p70S6K/pGSK3β were decreased with no change in retinal
IRS1/2 expression or tyrosine phosphorylation. Such rapid
signalling changes and alterations in p70S6K and GSK3β as a
result of hyperglycaemia provide further evidence of a role for
insulin signalling in retinal cell survival. After 3 months, IR-β
expression, autophosphorylation and kinase activity was
decreased in diabetic retina. Moreover, IRS2 protein expression
was decreased whereas IRS1 was unchanged. These data
suggest that IR signalling is compromised relatively early in the
diabetic retina, and suggests a critical role for reduced insulin
in IRS2 signalling in progressive retinal degeneration
Reiter et al (2006) [85]
P706K, phospho-p70 S6 kinase
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these data support the notion that changes in insulin signalling
during Alzheimer’s disease may represent an insulin-resistant
state in the brain, and that targeting these changes may im-
prove outcomes for Alzheimer’s patients [66].
IRS proteins in diabetic neuropathy
Diabetic neuropathy is a common complication of diabe-
tes, affecting 50% of patients. Many patients suffer from
nerve pain, reduced proprioception (the body’s ability to
sense joint movement and position) and peripheral insen-
sitivity, leading to foot ulcers that may in severe cases
require amputation [70]. Many different pathways have
been implicated in the pathogenesis of diabetic neuropathy,
including decreased neurotrophic growth factors such as
IGF-1 [71], advanced glycation end-products and oxidative
stress [72]. Impaired insulin signalling has been implicated
in the pathogenesis of diabetic neuropathy. Insulin is a
neurotrophic factor for the dorsal root ganglion, and IRS
proteins are expressed in these cells, with IRS2 expression
being most abundant in both myelinated and unmyelinated
Table 4 Summary of animal model data implicating IRS proteins in diabetic neuropathy
IRS involved Rodent genotype/
phenotype
Organ affected Main finding(s) Reference
IR, IRS1 ob/ob mice (model of
type 2 diabetes)
Spinal dorsal horn
region of the
spinal cord
Diabetic ob/ob mice displayed PDN in the form of mechanical
hyperalgesia, as demonstrated by low paw-withdrawal
thresholds. This decrease in withdrawal threshold coincided
with reduced p-IRS1 and IR-positive spinal dorsal horn
neurons in these mice. As PDN progresses, IR and p-IRS1
levels decline. Also, with progression of PDN, pJAK2 and
p-STAT3 levels increase, with specific activation of
JAK2/STAT3 occurring in this area. Administration of a
JAK2/STAT3 pathway inhibitor reverts the pain threshold
to normal levels in ob/obmice. The JAK/STAT inhibitor also
prevented the decrease in IR and p-IRS1, suggesting a link
between JAK/STAT, IR/IRS1 signalling and PDN
Kou et al (2013) [73]
IRS2 Diabetic GK rats Neurons Oral administration of vildagliptin reduced neuronal atrophy
and improved neuropathy as evaluated by motor and sensory
nerve conduction velocity. Vildagliptin preserved
intra-epidermal nerve fibre density in GK rats, which
indicates beneficial neuropathic effects. Vildagliptin increased
GLP-1 signals such as CREB; PKB/Akt phosphorylation in
the dorsal root ganglion, with changes in IRS2Tyr/IRS2Ser
phosphorylation also seen. Crosstalk exists between insulin
and GLP-1 at least in part through CREB phosphorylation,
which promotes IRS2 expression. Of note, hyperglycaemia in
these diabetic GK rats was unchanged following vildagliptin
treatment, suggesting that vildagliptin functions to inhibit
neuropathy development independently of hyperglycaemia
Tsuboi et al (2015)
[77]
IR-β, IRS1, IRS2 ZDF rats, a long-term
model of PDN
Sensory neurons and
dorsal root ganglion
Progressive slowing of nerve conduction in the ZDF rats is
detected. ZDF rats are more sensitive to mechanical
withdrawal (similar to ob/obmice), suggesting pain sensation
from a non-painful stimulation of the skin. Dorsal root
ganglion mRNA levels of IR-β, IRS1 and IRS2, Akt,
PI3K and GLUT4 were preserved or slightly increased in
ZDF rats
Brussee et al (2008)
[86]
IRS2 ob/ob mice (model of
type 2 diabetes), and
STZ C57BL/6 mice
(model of type
1 diabetes)
Dorsal root ganglion Total IRS2 levels decreased in diabetic ob/ob dorsal root
ganglion neurons. IRS2 Ser phosphorylation increases in
dorsal root ganglion neurons from diabetic ob/ob mice
and dorsal root ganglion neurons from an STZ mouse
model. Suboptimal dorsal root ganglion insulin signalling
may be caused by increased IRS serine phosphorylation,
leading to IRS degradation, decreasing IR/IRS
interaction. In healthy neurons, insulin increases neurite
outgrowth. Neurons from ob/ob mice were unable to
efficiently respond to insulin. Increased IRS2 serine
phosphorylation and subsequent insulin resistance may
modulate neuronal insulin signalling to promote peripheral
nerve dysfunction leading to PDN.
Aguirre et al (2000) [49];
Grote et al (2011)
[70]; Rui et al
(2001) [87]
CREB, cAMP response element binding protein; GK, Goto–Kakizaki (rats); PDN, painful diabetic neuropathy; ZDF, Zucker diabetic fatty (rats)
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neurons [70]. In animal models of diabetes, several reports
have identified a reduction in insulin sensitivity of dorsal
root ganglion cells (summarised in Table 4). Reduced
IRS2 expression was linked to hyperalgesia in diabetic
mice, which was reversed by inhibition of the
JAK2/signal transducer and activator of transcription 3
(STAT3) pathway [73]. Importantly, incretin drugs that
are widely used to treat type 2 diabetes have been shown
to reduce the severity of diabetic neuropathy in pre-clinical
models. Exendin-4, vildagliptin and alogliptin all improved
nerve conductance velocity in diabetic rats and reversed
nerve damage [74–76]. These effects were linked to an
improvement in both GLP-1 and insulin signalling, with
expression of IRS2 being increased in neurons from dia-
betic animals treated with vildagliptin [77]. Thus, the pres-
ervation or restoration of neuronal insulin signal transduc-
tion pathways and IRS2 expression would seem to be a
useful avenue for exploring new and improved therapeutic
interventions in diabetic neuropathy.
Concluding remarks
A summary of the role of IRS proteins in organs affected by
diabetic complications is shown in Fig. 1. It is clear from the
literature that reduced insulin signalling is implicated not just
in the aetiology of diabetes but also in the pathogenesis of
diabetic complications. Given their central role in insulin sig-
nalling, it is perhaps not surprising that abundant evidence
exists to show that IRS proteins are implicated in vascular
complications of diabetes. A slew of mouse data and genetic
studies in human patients strengthen the argument that chang-
es in IRS function contribute to diabetic complications in af-
fected organs such as the heart, kidney, eye and nervous sys-
tem. The vascular aetiology of many diabetic complications
makes it reasonable to assume that changes in IRS protein
expression or phosphorylation occur as a result of chronic
hyperglycaemia, which triggers vascular damage. Data from
mice showing that increasing IRS2 levels provides relief in
terms of hepatic insulin resistance are very encouraging.
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IR      VEGF       Podocyte survival
Insulin signalling
IRS proteins
Ruboxistaurin
PKCβ2
Phosphorylation 
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Increased severity
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Poorer cardiac 
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Fig. 1 IRS proteins in organs affected by diabetic complications. A se-
lection of data from animal and human studies supporting changes in IRS
proteins during diabetic heart disease (pink panel), diabetic nephropathy
(purple panel), diabetic retinopathy (green panel), diabetic vascular dis-
ease (yellow panel), diabetic neuropathy (orange panel) and Alzheimer’s
disease (blue panel). Details and supporting references are provided in the
text. Red T-bar represents inhibition; green arrow represents activation;
black arrow represents ‘leading to’. AngII, angiotensin II; βAR, β-adren-
ergic receptor; PDN, painful diabetic neuropathy
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Emerging gene-editing technologies, such as CRISPR (clus-
tered regularly interspaced short palindromic repeats)/Cas9
and TALENS (transcription activator-like effector nucleases),
will allow deletion or insertion of IRS1, IRS2 or both proteins
in vascular cells damaged in diabetes. These future experi-
ments will shed new light on the role of IRS proteins in dia-
betic vascular complications, and also expand our ability to
provide novel therapeutic strategies aimed at boosting IRS
protein levels and improving the outcomes for patients with
diabetic complications.
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